Noema Pharma AG
Basimglurant
Trigeminal Neuralgia
Countdown
210days
Phase 3 readout · Feb 2, 2027
What's at stake
Phase 3 trial results for Basimglurant in Trigeminal Neuralgia are due Feb 2, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05217628: Phase 3 trial, sponsor Noema Pharma AG, drug Basimglurant. Primary completion date 2027-02-02 (estimated).”